North Star Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.39M | Sell |
6,833
-26
| -0.4% | -$11.5K | 0.13% | 117 |
|
|
2026
Q1 | $3.06M | Hold |
6,859
| – | – | 0.13% | 121 |
|
|
2025
Q4 | $3.11M | Sell |
6,859
-24
| -0.3% | -$10.3K | 0.13% | 119 |
|
|
2025
Q3 | $2.7M | Hold |
6,883
| – | – | 0.11% | 130 |
|
|
2025
Q2 | $3.06M | Buy |
6,883
+864
| +14% | +$398K | 0.13% | 116 |
|
|
2025
Q1 | $2.92M | Buy |
6,019
+196
| +3% | +$91.3K | 0.13% | 115 |
|
|
2024
Q4 | $2.34M | Buy |
5,823
+100
| +2% | +$46.4K | 0.1% | 127 |
|
|
2024
Q3 | $2.66M | Hold |
5,723
| – | – | 0.12% | 118 |
|
|
2024
Q2 | $2.68M | Hold |
5,723
| – | – | 0.13% | 118 |
|
|
2024
Q1 | $2.39M | Sell |
5,723
-2
| -0% | -$845 | 0.11% | 125 |
|
|
2023
Q4 | $2.33M | Buy |
5,725
+5
| +0.1% | +$1.85K | 0.12% | 122 |
|
|
2023
Q3 | $1.99M | Hold |
5,720
| – | – | 0.11% | 131 |
|
|
2023
Q2 | $2.01M | Buy |
5,720
+5
| +0.1% | +$1.69K | 0.11% | 130 |
|
|
2023
Q1 | $1.8M | Sell |
5,715
-35
| -0.6% | -$10.5K | 0.11% | 131 |
|
|
2022
Q4 | $1.66M | Hold |
5,750
| – | – | 0.1% | 127 |
|
|
2022
Q3 | $1.67M | Sell |
5,750
-25
| -0.4% | -$7.19K | 0.11% | 126 |
|
|
2022
Q2 | $1.63M | Hold |
5,775
| – | – | 0.11% | 129 |
|
|
2022
Q1 | $1.51M | Hold |
5,775
| – | – | 0.08% | 145 |
|
|
2021
Q4 | $1.27M | Hold |
5,775
| – | – | 0.06% | 152 |
|
|
2021
Q3 | $1.05M | Buy |
5,775
+2,100
| +57% | +$410K | 0.06% | 156 |
|
|
2021
Q2 | $741K | Buy |
3,675
+25
| +0.7% | +$5.23K | 0.04% | 178 |
|
|
2021
Q1 | $784K | Hold |
3,650
| – | – | 0.05% | 170 |
|
|
2020
Q4 | $863K | Hold |
3,650
| – | – | 0.05% | 155 |
|
|
2020
Q3 | $993K | Hold |
3,650
| – | – | 0.07% | 132 |
|
|
2020
Q2 | $1.06M | Hold |
3,650
| – | – | 0.08% | 127 |
|
|
2020
Q1 | $869K | Sell |
3,650
-300
| -8% | -$68.8K | 0.08% | 127 |
|
|
2019
Q4 | $865K | Hold |
3,950
| – | – | 0.06% | 163 |
|
|
2019
Q3 | $669K | Hold |
3,950
| – | – | 0.05% | 176 |
|
|
2019
Q2 | $724K | Hold |
3,950
| – | – | 0.06% | 170 |
|
|
2019
Q1 | $727K | Hold |
3,950
| – | – | 0.06% | 163 |
|
|
2018
Q4 | $655K | Hold |
3,950
| – | – | 0.06% | 167 |
|
|
2018
Q3 | $761K | Hold |
3,950
| – | – | 0.06% | 171 |
|
|
2018
Q2 | $671K | Hold |
3,950
| – | – | 0.06% | 177 |
|
|
2018
Q1 | $644K | Hold |
3,950
| – | – | 0.06% | 179 |
|
|
2017
Q4 | $592K | Buy |
+3,950
| New | +$585K | 0.05% | 190 |
|
Other funds holding VRTX
North Star Asset Management's VRTX Position: Q2 2026 in Review
North Star Asset Management reduced its Vertex Pharmaceuticals (VRTX) stake by 0.38% in Q2 2026, selling an estimated $11.5K and leaving 6,833 shares worth $3.39M. The position accounts for 0.13% of the portfolio, ranked #117.
North Star Asset Management first reported a position in VRTX in Q4 2017 and has held it in 35 quarters since. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- North Star Asset Management held 6,833 shares of Vertex Pharmaceuticals worth $3.39M as of Q2 2026.
- North Star Asset Management sold 26 Vertex Pharmaceuticals shares in Q2 2026, an estimated $11.5K.
- Vertex Pharmaceuticals made up 0.13% of North Star Asset Management's portfolio in Q2 2026, its #117 holding.
- North Star Asset Management first reported a position in Vertex Pharmaceuticals in Q4 2017 and has held it in 35 quarters since.
- 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on North Star Asset Management's 13F filing for Q2 2026, filed 18 Aug 2026.